Clinical Trials

The clinical trial landscape for Ritodrine HCl includes a clinical trial dedicated to evaluating its pharmacological safety and tolerability. Sponsored by an academic medical center, University Hospital Ghent, this completed Phase I study investigated healthy female subjects to determine dose-response characteristics and identify the maximum well-tolerated dose. Overall, the available evidence highlights early-stage clinical evaluation focused on baseline tolerability in a healthy demographic.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00679705 Completed
Healthy
University Hospital Ghent
 2008-05 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ritodrine HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ritodrine HCl selectively binds to and stimulates beta-2 adrenergic receptors on uterine smooth muscle cells, activating membrane-bound adenylate cyclase to elevate intracellular cyclic adenosine monophosphate (cAMP) levels. This signaling cascade decreases intracellular calcium concentration and reduces myosin light chain kinase activity, leading to uterine muscle relaxation and suppression of uterine contractions to prevent premature labor.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.